Fiera Capital Corp Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fiera Capital Corp decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139,923 shares of the medical research company’s stock after selling 316 shares during the quarter. Fiera Capital Corp’s holdings in Thermo Fisher Scientific were worth $86,552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in TMO. Signature Resources Capital Management LLC increased its holdings in Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock worth $25,000 after acquiring an additional 35 shares during the period. New Millennium Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at $29,000. Stephens Consulting LLC boosted its position in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 29 shares during the last quarter. Headlands Technologies LLC bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $32,000. Finally, Bank & Trust Co bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $33,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.3 %

TMO traded down $1.89 during trading on Friday, reaching $554.00. The stock had a trading volume of 412,588 shares, compared to its average volume of 1,455,518. Thermo Fisher Scientific Inc. has a one year low of $437.26 and a one year high of $627.88. The company has a market capitalization of $211.91 billion, a price-to-earnings ratio of 34.77, a P/E/G ratio of 3.70 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average is $596.33 and its two-hundred day moving average is $583.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Analyst Ratings Changes

A number of research analysts recently commented on TMO shares. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Barclays decreased their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the completion of the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,611,804.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,150 shares of company stock worth $10,094,925 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.